Portions of this exhibit marked [*] have been granted confidential treatment. MASTER DEVELOPMENT SERVICES AGREEMENTMaster Development Services Agreement • June 18th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
THIS MASTER DEVELOPMENT SERVICES AGREEMENT (the “Agreement”) is made and entered into as of June 14, 2010 (the “Effective Date”) by and between PPD DEVELOPMENT, LP, a Texas limited partnership, with its principal executive offices located at 929 North Front Street, Wilmington, North Carolina 28401 (“PPD”), and FURIEX PHARMACEUTICALS, INC., a Delaware corporation with its principal executive offices located at 3900 Paramount Parkway, Suite 150, Morrisville, North Carolina 27560 (“Sponsor”).
TRANSITION SERVICES AGREEMENTTransition Services Agreement • June 18th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations
This Transition Services Agreement (the “Agreement”) is entered into as of the 14th day of June, 2010, by and between Pharmaceutical Product Development, Inc., a North Carolina corporation (“PPD”), and Furiex Pharmaceuticals, Inc., a Delaware corporation (“Furiex”).
SUBLEASE AGREEMENTSublease Agreement • June 18th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS SUBLEASE AGREEMENT (“Sublease”) made and entered into this 14th day of June, 2010, by and between PPD DEVELOPMENT, LP, a Texas limited partnership (“Sublessor”) and Furiex Pharmaceuticals, Inc., a Delaware corporation (“Sublessee”).
EMPLOYEE MATTERS AGREEMENT by and between PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. and FURIEX PHARMACEUTICALS, INC. Dated as of June 14, 2010 EMPLOYEE MATTERS AGREEMENTEmployee Matters Agreement • June 18th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
EMPLOYEE MATTERS AGREEMENT (this “Agreement”), dated as of June 14, 2010, by and between Pharmaceutical Product Development, Inc., a North Carolina corporation (“PPD”), and Furiex Pharmaceuticals, Inc., a Delaware corporation (“Furiex”). Each of PPD and Furiex is herein referred to as a “Party” and collectively, as the “Parties”.
SEPARATION AND DISTRIBUTION AGREEMENT by and between PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. and FURIEX PHARMACEUTICALS, INC. Dated as of June 14, 2010Separation and Distribution Agreement • June 18th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
THIS SEPARATION AND DISTRIBUTION AGREEMENT (including all Exhibit and Schedules hereto, the “Agreement”), dated as of June 14, 2010, is entered into by and between Pharmaceutical Product Development, Inc., a North Carolina corporation (“PPD”), and Furiex Pharmaceuticals, Inc., a Delaware corporation (“Furiex”) (each a “Party” and collectively, the “Parties”). Capitalized terms used herein and not otherwise defined shall have the respective meanings assigned to them in Article I hereof.
TAX SHARING AGREEMENTTax Sharing Agreement • June 18th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
This Tax Sharing Agreement (this “Agreement”) is entered into as of June 14, 2010 between Pharmaceutical Product Development, Inc., a North Carolina corporation (“PPD”), and Furiex Pharmaceuticals, Inc., a Delaware corporation that currently is wholly owned subsidiary of PPD (“Furiex” each of PPD and Furiex is a “Party” and, together are the “Parties”. Terms used in this Agreement and not otherwise defined herein shall have the meanings ascribed to such terms in the Separation and Distribution Agreement, dated as of the date hereof, by and between PPD and Furiex (the “Separation Agreement”).
CONSULTING AGREEMENTConsulting Agreement • June 18th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
This CONSULTING AGREEMENT (the “Agreement”) is made and entered into this 14th day of June, 2010, by and among Furiex Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Elk Mountain Consulting, LLC, a Wyoming limited liability company (the “Consultant”), and as to Sections 5 and 6 of the Agreement only, Fredric N. Eshelman (“Dr. Eshelman”).
